Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines

J Bouchal, Karl Baumforth, M Svachova, Paul Murray, E von Angerer, Z Kolar

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Bicalutamide is a non-steroidal anti-androgen commonly used in the treatment of prostate carcinoma. We analysed the transcriptional response to bicalutamide treatment with the aim of Explaining the inhibition of telomerase in the androgen-sensitive cell line LNCaP and the effects 0 bicalutamicle on the androgen-insensitive cell line DU145. Cells treated with 80 mum bicalutamide in steroid-depleted medium for 1 day were analysed in duplicate by Affymetrix Human Genome Focus Arrays. Response to bicalutamicle in LNCaP cells was represented by downregulation of androgenregulated genes, activation of the p53 pathway and inhibition of telomerase, which was associated with downregulation of v-myc avian myelocytomatosis viral oncogene homologue (MYC) and telomerase reverse transcriptase subunit. In DU145 cells we observed the influence of cell density on bicalutamide effectivity such that highly confluent cells showed lesser sensitivity than love confluent ones. In conclusion, we provide an explanation for telomerase inhibition after androgen receptor blockade in LNCaP cells and we also report activation of the p53 pathway in LNCaP cells and in-vitro sensitivity to bicalutamide of low confluent androgen-insensitive DU145 cells. These findings might have implications for both experimental and clinical research into prostate cancer. In particular, activation of the p53 pathway after treatment with 80 mum, bicalutamide could justify usage of bicalutamicle dosages higher than 150 mg daily in androgen-sensitive carcinoma therapy.
Original languageEnglish
Pages (from-to)83-92
Number of pages10
JournalJournal of Pharmacy and Pharmacology
Volume57
Issue number1
DOIs
Publication statusPublished - 1 Jan 2005

Fingerprint

Dive into the research topics of 'Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines'. Together they form a unique fingerprint.

Cite this